Clinically isolated syndrome (CIS) is a term that describes the first clinical onset of potential multiple sclerosis (MS). The term CIS is typically applied to young adults with episodes of acute or subacute onset, which reaches a peak quite rapidly within 2-3 weeks. In 85% of young adults who develop MS, onset occurs with an acute, CIS of the optic nerves, brainstem, or spinal cord. When clinically silent brain lesions are seen on MRI, the likelihood of developing MS is high. Because no single clinical feature or diagnostic test is sufficient for the diagnosis of CIS, diagnostic criteria have included a combination of both clinical and paraclinical studies. 
temic lupus erythematosus and neuroborreliosis) that are commonly part of the differential diagnosis can be investigated through blood and CSF analyses (4). Table 2 categorizes CIS presentations of patients eventually diagnosed as having MS into (i) those that are typical of patients eventually diagnosed as having MS, (ii) those that are less common but nevertheless may be an initial presentation in patients eventually diagnosed with MSor may signal another disease, and (iii) those that are atypical, suggesting an alternative diagnosis (6) .
Magnetic resonance imaging is a crucial investigation for the differentiation of brainstem and spinal cord CIS owing to inflammatory demyelination from other structural lesions (e.g., brainstem vascular malformation and cord compression) (6) . MRI can also influence a decision as to whether a presentation is due to monofocal or multifocal lesions and the likelihood for the ultimate diagnosis of MS (Table 3 ) (6).
The three most common CIS syndromes seen at presentation in MS diagnosis include those affecting the optic nerve, brain stem, and spinal cord (6) . In patients with suspected optic neuritis, there are many clinical features that suggest a cause other than inflammatory demyelination (4) . Figures 2, 3, and 4 show clinical aspects that are typical for demyelination as seen in MS and atypical features that should trigger a consideration of other diagnoses (1, 6) .
CSF
Although CSF OCBs increase the risk of CIS developing into MS, they add little to MRI-assigned risk. Tintore et al. (7) recorded a conversion to MS in 59% of all patients with CIS with more than 10 brain lesions and in 64% of patients who had more than 10 brain lesions and CSF OCBs. For MS diagnosis or prediction, many neurologists think that MRI alone is sufficient. However, CSF examination helps predict the conversion to MS in patients with a negative MRI or with MRI showing few lesions (i.e., MRI that does not meet the McDonald criteria for dissemination in space). In patients with negative MRI, the presence of OCBs increases the risk for developing MS from 4% to 23%. Therefore, the development of MS is unlikely in patients with CIS showing few or no MRI lesions and no CSF OCBs (1) .
Typical CSF findings in MS include a slightly elevated leukocyte count (5-50 cells per μL compared with a normal range of <5 cells per μl), the presence of activated B cells or plasma cells on cytological analysis, S2 elevated immunoglobulin G (IgG) synthesis, OCBs, and an increased synthesis of intrathecally produced immunoglobulins against measles, rubella, and varicella zoster viruses (Table 4) . CSF albumin levels and the CSF albumin:serum ratio (an accurate measure of the integrity of the blood-CSF barrier) are usually normal but can be elevated in some patients with MS. Normal CSF findings are present in up to 10% of patients with MS (8).
Although a typical constellation of CSF findings can support the diagnosis of MS, it is by no means pathognomonic for this disease. However, deviations from typical CSF findings can aid in making a correct diagnosis, which is important for the management of patients (8) .
DIAGNOSTIC CRITERIA
Diagnostic criteria for MS have evolved over the past 50 years. Although successive versions have differed in emphasis, all have required the dissemination of disease in space and time documented by either clinical, paraclinical, or laboratory criteria. Additionally, MS diagnostic criteria have emphasized that an alternative explanation for the clinical presentation must be considered and excluded before the diagnosis of MS can be made (6) .
POSER CRITERIA
The main reason for establishing these criteria is to restrict therapeutic trials and other research protocols to patients with DMS, while the category of probable is designed for the purpose of prospectively evaluating new diagnostic methods (9) . In 1983, the diagnostic criteria of Poser et al. (9) were published. Originally, they were developed as guidelines for use in research protocols, but they also became widely applied in clinical practice. Two major groups were defined, "definite" and "probable" MS, each with two subgroups: "clinically definite" and "laboratory supported. " The Arch Neuropsychiatr 2015; 52: (Supplement 1): S1-11 Efendi H. Clinically Isolated Syndromes Dalton et al. (2) showed that the use of McDonald criteria more than doubled the rate of the diagnosis of MS within a year of presentation with CIS. The high specificity, positive predictive value, and accuracy of the criteria for CDMS support their clinical relevance (2).
S3
In the years since their original presentation, several publications have appeared that support the utility of the McDonald criteria: Retrospective analyses of extent datasets have shown that the criteria could reliably signal the development of CDMS earlier than prior criteria and that they had a reasonably high level of specificity and sensitivity compared with those of prior criteria. Additional published studies have explored potential modifications of the original criteria, with particular emphasis on determining the dissemination of lesions in time and space (the core concept in MS diagnosis), incorporating different types of imaging criteria to the diagnostic scheme, and assessing the value of CSF analysis, particularly for the diagnosis of primary progressive MS (PPMS) (11).
Although Dalton et al. (12) demonstrated that a new T2 lesion at 3 months is a reliable marker of dissemination in time, there was a median of 5 weeks from the onset of symptoms to the baseline MRI scan in their studies. The International Panel on Diagnosis of MS (the Panel) believed that T2 lesions could be useful for demonstrating dissemination in time more rapidly than over the 3-month period required in the original McDonald criteria, but it agreed that T2 lesions occurring in the first few weeks after the onset of the first clinical episode should not be considered a separate, new event. Practically any new T2 lesion occurring at any time point after a so-called reference scan performed at least 30 days after the onset of the initial clinical event is useful in fullfilling imaging diagnostic criteria for dissemination in time. This revision would simplify and clarify the prior criteria, allow for a more rapid diagnosis, and provide S4 more flexibility in imaging criteria, while still carrying an unequivocal proof of dissemination in time (Table 6 ) (11).
The original McDonald criteria set out specific criteria that needed to be fulfilled largely based on brain MRI scan outcomes to demonstrate a diagnostically relevant brain abnormality. These criteria, from the work of Barkhof et al. (13) as modified by Tintore et al. (7), include evidence for three of the following four outcomes: one gadolinium-enhancing lesion or nine T2-hyperintense lesions if there is no gadolinium-enhancing lesion, at least one infratentorial lesion, at least one juxtacortical lesion, or at least three periventricular lesions ( Table 7) . As noted, the Panel concluded that although it is biologically plausible to liberalize these requirements for "positive" MRI indicating MS-like brain abnormality, the lack of prospective data to test the specificity and sensitivity of any such liberalized criteria make it unwise at this point to change these criteria (11) .
It was recommended in the original McDonald criteria that "one spinal cord lesion can be substituted for one brain lesion, " a statement that in retrospect is confusing and provides insufficient guidance for the use of spinal cord imaging in the diagnostic workup. At its Amsterdam meeting, the Panel also reached a consensus on the revisions and guidance related to spinal cord lesions (11) .
The Panel continues to believe that a positive CSF finding (preferably based on isoelectric focusing evidence of oligoclonal IgG bands with imArch Neuropsychiatr 2015; 52: (Supplement 1): S1-11 Efendi H. Clinically Isolated Syndromes munofixation, demonstrating that bands are different from those in serum or an increased IgG index or both) increases the "comfort level" for the diagnosis of MS in individuals with an insidious progression of the disease from the onset. However, such CSF findings are not specific and may be commonly detected in patients with progressive myelopathies of other causes, particularly those associated with infection (e.g., retrovirus). Depending on the strength of other diagnostic criteria, a positive CSF finding is no longer a requirement for the diagnosis of PPMS (Table 8 ) (11).
S5
The 2005 Revisions of the MS diagnostic criteria (Table 9 ) retain the core features of the original McDonald criteria: emphasis on objective clinical findings, dependence on the evidence of the dissemination of lesions in time and space, use of supportive and confirmatory paraclinical examinations to speed the process and help eliminate false-negative and -positive diagnoses, a focus on specificity rather than sensitivity, and a need to eliminate better explanations for the diagnosis (11).
MCDONALD CRITERIA: 2010 REVISIONS
New evidence and consensus has led to a further revision of the McDonald criteria for the diagnosis of MS. In May 2010 in Dublin, Ireland, the Panel met for a third time to examine the requirements for demonstrating DIS and DIT and to focus on the application of the McDonald criteria S6 Table 6 . Magnetic resonance imaging criteria to demonstrate dissemination of lesions in time (11) Original McDonald criteria
1.
If a first scan occurs 3 months or more after the onset of the clinical event, the presence of a gadolinium-enhancing lesion is sufficient to demonstrate dissemination in time, provided that it is not at the site implicated in the original clinical event. If there is no enhancing lesion at this time, a follow-up scan is required. The timing of this follow-up scan is not crucial, but 3 months is recommended. A new T2-or gadolinium-enhancing lesion at this time then fulfills the criterion for dissemination in time.
2.
If the first scan is performed less than 3 months after the onset of the clinical event, a second scan done 3 months or longer after the clinical event showing a new gadolinium-enhancing lesion provides sufficient evidence for dissemination in time. However, if no enhancing lesion seen at this second scan, a further scan not less than 3 months after the first scan that shows a new T2 lesion or an enhancing lesion will suffice.
revisions

1.
There are two ways to show dissemination in time using imaging; a. Detection of gadolinium enhancement at least 3 months after the onset of the initial clinical event, if not at the site corresponding to the initial event.
b. Detection of a new T2 lesion if it appears at any time compared with a reference scan done at least 30 days after the onset of the initial clinical event. Table 7 . Magnetic resonance imaging criteria to demonstrate brain abnormality and demonstration of dissemination in space (11)
Original McDonald criteria
Three of the following: c. Positive CSF a (isoelectric focizing evidence of oligoclonal lgG bands or increased lgG index, or both).
in pediatric, Asian, and Latin American populations. The use of imaging for the demonstration of the dissemination of CNS lesions in space and time has been simplified, and in some circumstances, the dissemination in space and time can be established by a single scan. These revisions simplify the criteria, preserve their diagnostic sensitivity and specificity, address their applicability across populations, and may allow earlier diagnosis and their more uniform and widespread use (Table 10 ) (15).
In the past versions of the McDonald criteria, DIS demonstrated by MRI was based on the Barkhof/Tintore (13, 14) criteria. Despite having good sensitivity and specificity, these criteria have been difficult to consistently apply by nonimaging specialists. The European MAGNIMS multicenter collaborative research network, which studies MRI in MS, compared the Barkhof/Tintore (13,14) criteria for DIS with simplified criteria developed by Swanton et al. (16, 17) .
In the MAGNIMS work, DIS can be demonstrated with at least one T2 lesion in at least two of four locations considered characteristic for MS and as specified in the original McDonald criteria (juxtacortical, periventricular, infratentorial, and spinal cord), with lesions within the symptomatic region excluded in patients with brainstem or spinal cord syndromes. In 282 patients with CIS, the Swanton-based DIS criteria were shown to be simpler and slightly more sensitive than the original McDonald criteria for DIS, without compromising specificity and accuracy. The Panel accepted these MAGNIMS DIS criteria, which can simplify the diagnostic process for MS while preserving specificity and improving sensitivity (15, 16) .
More recently, the MAGNIMS group confirmed earlier studies by showing that in patients with typical CIS, a single brain MRI study that demonstrates DIS and both asymptomatic gadolinium-enhancing and nonenhancing lesions is highly specific for predicting the early development of CDMS and reliably substitutes prior imaging criteria for DIT. After reviewing these data, the Panel accepted that the presence of both gadolinium-enhancing and nonenhancing lesions on the baseline MRI can substitute for a follow-up scan to confirm DIT, as long as it can be reliably determined that the gadolinium-enhancing lesion is not due to a non-MS pathology (15) .
MANAGEMENT OF CIS
Many CIS episodes are mild and are resolved without therapeutic intervention. Clinical features that favor treatment include severe visual loss, pain in optic neuritis, or both, and pronounced motor dysfunction, ataxia, or vertigo in spinal cord and brainstem syndromes (1, 6) .
Corticosteroids are used when the symptoms are functionally disabling or when patients do not spontaneously improve (6) . High-dose intravenous methylprednisolone in acute optic neuritis shortens the duration Arch Neuropsychiatr 2015; 52: (Supplement 1): S1-11 Efendi H. Clinically Isolated Syndromes If criteria indicated are fulfilled and there is no better explanation for the clinical presentation, the diagnosis is MS; if suspicious, but the criteria are not completely met, the diagnosis is "possible MS"; if another diagnosis arises during the evaluation that better explains the entire clinical presentation, then the diagnosis is "not MS. " a An attack is defined as an episode of neurological disturbance for which causative lesions are likely to be inflammatory and demyelinating in nature. There should be subjective report (backed up by objective findings) or objective observation that the event lasts for at least 24 hours. b No additional tests are required; however, if tests (MRI, CSF) are undertaken and are negative, extreme caution needs to be taken before making a diagnosis of MS. Alternative diagnoses must be considered. There must be no better explanation for the clinical picture and some objective evidence to support a diagnosis of MS. c MRI demonstration of space dissemination must fulfill the criteria in Table 10 . Table 9 . of visual deficits but not the visual outcome after 1 year. Oral high-dose methylprednisolone (1 g per day for 3-5 days) is probably an acceptable alternative to intravenous methylprednisolone (1 g per day for 3-5 days) (1) . Patients treated with intravenous methylprednisolone and oral prednisone have a lower risk of developing CDMS over the next 2 years than those given a placebo (9% vs. 17%, respectively). However, after the third year of follow-up, the treatment and placebo groups' risks of conversion to CDMS did not differ (6) .
S7
β-interferon and glatiramer acetate extend the time to the next relapse of CDMS. Patients treated with intramuscular β-interferon-1a (30 μg) once a week had a 37% conversion to CDMS after 2 years compared with a 50% conversion of those who received a placebo. Weekly subcutaneous β-interferon-1a (22 μg) was associated with a 35% conversion to MS after 2 years compared with a 50% conversion in those given a placebo. Subcutaneous β-interferon-1b (250 mg) on alternate days reduced the conversion to CDMS from 55% (in placebo) to 35% after 2 years. Daily subcutaneous glatiramer acetate (30 mg) was associated with a 35% conversion to CDMS compared with a 50% conversion in the placebo group. These treatments also reduce new MRI lesion formation and might slow down brain atrophy (1) .
In addition to the suppression of inflammation, the challenge exists for treatments to prevent neurodegeneration as CIS evolves to MS and beyond. Ultimately, a combination of anti-inflammatory and neuroprotective treatments might be needed to prevent long-term disability. Strategies for S8 If the criteria are fulfilled and there is no better explanation for the clinical presentation, the diagnosis is ''MS''; if suspicious, but the criteria are not completely met, the diagnosis is ''possible MS''; if another diagnosis arises during the evaluation that better explains the clinical presentation, then the diagnosis is ''not MS. '' a An attack (relapse; exacerbation) is defined as patient-reported or objectively observed events typical of an acute inflammatory demyelinating event in the CNS, current or historical, with duration of at least 24 hours, in the absence of fever or infection. It should be documented by contemporaneous neurological examination, but some historical events with symptoms and evolution characteristic for MS, but for which no objective neurological findings are documented, can provide reasonable evidence of a prior demyelinating event. Reports of paroxysmal symptoms (historical or current) should, however, consist of multiple episodes occurring over not less than 24 hours. Before a definite diagnosis of MS can be made, at least 1 attack must be corroborated by findings on neurological examination, visual-evoked potential response in patients reporting prior visual disturbance, or MRI consistent with demyelination in the area of the CNS implicated in the historical report of neurological symptoms.
b Clinical diagnosis based on objective clinical findings for 2 attacks is most secure. Reasonable historical evidence for 1 past attack, in the absence of documented objective neurological findings, can include historical events with symptoms and evolution characteristics for a prior inflammatory demyelinating event; at least 1 attack, however, must be supported by objective findings.
neuroprotection include sodium-channel blockers, statins, glutamate antagonists, and remyelination with stem cells and other molecular targets that promote repair. However, no effective neuroprotective agent has yet been identified for MS (1).
DIAGNOSIS AND TREATMENT OF INDIVIDUAL PATIENTS
According to Miller et al. (4) , most clinicians who see patients with CIS or suspected early MS agree that it is important to diagnose early and having done so, to weigh-up the potential benefits, risks, and uncertainties of disease-modifying treatment, while ensuring that the patient is kept fully informed and participates in the decision-making (4). (Table 11 ) (18) . The PreCISe trial studied GA in patients with CIS and has also shown superior efficacy to placebos, although the full results are still pending, and thus will not be considered further here, except to note that arguments made in favor of early IFN beta therapy are likely to apply equally to GA (Table 12 ) (19) (20) (21) (22) (23) (24) .
CIS MANAGEMENT IN CLINICAL TRIALS
As the CIS stage represents the first opportunity for treatment in most patients, many neurologists advocate starting therapy at this point. Of the available treatments, only 30 mg of IFNb-1a by weekly intramuscular (im) injection and 250 mg of IFNb-1b by subcutaneous (sc) injection every other day are currently licensed for the treatment of patients with a CIS suggestive of MS. Nevertheless, low-dose 22 mg of IFNb-1a by sc injection once weekly has also been demonstrated to be effective in CIS, and a recent placebo-controlled trial of 20 mg of GA by daily sc administration was stopped early at the 3-year interim analysis due to the superiority of the treatment arm. Thus, in reality, the use of any of these agents is appropriate in the clinical context of a CIS (18) .
The CHAMPS study enrolled 383 patients with CIS with monofocal disease randomized to two groups: 193 were given once-weekly 30 mg of IFNb-1a, im, and 190 were given weekly placebo injections. The development of CDMS was defined by the occurrence of a second attack or an increase of at least 1.5 points on the EDSS. The 30 mg IFNb-1a im treated group demonstrated a 44% reduction in the 3-year cumulative probability Arch Neuropsychiatr 2015; 52: (Supplement 1): S1-11 Efendi H. Clinically Isolated Syndromes of developing CDMS (rate ratio 0.56, 95% confidence interval 0.38 to 0.8; p=0.002) (18, 25) . At 18 months, treatment with 30 mg of IFNb-1a im was associated with a significant reduction of new T2 lesions, gadolinium enhanced lesions, and T2 lesion volume. Among the placebo-treated patients, 82% had developed a new subclinical MRI signal abnormality by the eighteenth month after study entry (25) .
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In the ETOMS trial, 309 patients with CIS were randomized to once-weekly injections of 22 mg of IFNb-1a sc (n=154) or a placebo (n=155). A significantly higher proportion of patients in the placebo group than the IFNb-1a group (45% vs. 34%, respectively; rate ratio 0.65; p=0.047) converted from CIS to CDMS (as defined by the occurrence of a second clinical attack) over the 2-year course of the study (19, 20) . The time when 30% of patients had converted to CDMS was 569 days in the interferon group and 252 in the placebo group (p=0.034). The annual relapse rates were 0.33 and 0.43 (p=0.045). The number of new T2-weighted MRI lesions and the increase in lesion burden were significantly lower with active treatment. The ETOMS group concluded that interferon beta-1a treatment at an early stage of DMS had significant positive effects on clinical and MRI outcomes (24) .
The BENEFIT study randomized 468 patients with CIS to two groups receiving injections of either 250 µg of IFNb-1b sc (n=292), or a placebo (n=176) every other day. As in the other two studies, the IFNb group showed a significantly lower rate of conversion from CIS to CDMS, as defined by a second event or an increase of at least 1.5 points on the EDSS. According to proportional hazards regression, the 2-year cumulative probability for CDMS was 28% in the IFNb-1b group and 45% in the placebo group (rate ratio 0.5; p<0.0001). In addition to defining CDMS by the Poser criteria, the BENEFIT study also employed the new international criteria to define progression to MS. In this analysis, again, treatment with IFNb-1b was associated with a reduction in the progression to International MS within 2 years, compared with placebo (rate ratio 0.54; p<0.00001) (18, 24, 25) . The BENEFIT group concluded that interferon beta-1b 250 µg subcutaneously every other day delayed the conversion to CDMS and should be considered as a therapeutic option in patients presenting with a first clinical event suggestive of MS (20) .
The PRECISE study randomized 481 patients presenting with CIS with unifocal manifestation, and two or more T2-weighted brain lesions measuring 6 mm or more. Patients were randomly assigned to receive either subcutaneous glatiramer acetate 20 mg per day (n=243) or a placebo (n=238) for up to 36 months, unless they converted to CDMS. The randomization scheme used SAS-based blocks stratified by center and patients, and all the personnel were masked to treatment assignment. In the Early Treatment of MS (ETOMS) study, subcutaneous interferon beta-1a at 22 μg once a week was effective in delaying MS. However, until now the effect of subcutaneous interferon beta-1a at 44 μg three times a week-the licensed dosing regimen for MS-has not been assessed in people with a clinically isolated event. In REbif FLEXible dosing in early MS [REFLEX] study, which was a 2-year, double-blind phase 3 study, the effects of two dosing frequencies of a serum-free formulation of subcutaneous interferon beta-1a at 44 μg and a placebo on the time to develop MS, as defined in the 2005 version of the McDonald criteria, were compared. This study is the first comparison of the efficacy of two dosing frequencies of subcutaneous interferon beta-1a. Participants were randomly assigned in a 1:1:1 ratio by use of a centralized interactive voice response system to receive the serum-free formulation of subcutaneous interferon beta-1a at 44 μg three times a week or once a week (plus placebo twice a week for masking), or placebo three times a week for up to 24 months. The primary endpoint was the time to a diagnosis of MS as defined by the 2005 McDonald criteria and the main secondary endpoint was the time to develop CDMS as defined by the Poser criteria. 517 patients were randomly assigned (171 to subcutaneous interferon beta-1a three times a week, 175 to subcutaneous interferon beta-1a once a week, and 171 to placebo) and 515 were treated. The 2-year cumulative probability of McDonald MS was significantly lower in patients treated with subcutaneous interferon beta-1a (three times a week 62.5%, p<0. Comi et al. (24) indicated that the long-term differences between interferon beta-1a three times a week and interferon beta-1a once a week, in terms of the effect on MRI-related disease activity and adverse-event profile, warrants further study and is the focus of the ongoing preplanned, dose-frequency-blinded, 3-year extension of this study (REFLEXION-RE-FLEX extensION study) (19) .
CONCLUSION
Clinically isolated syndrome describes a single, first-occurrence attack caused by inflammation/demyelination at one or more locations in CNS (1). Patients with CIS (and abnormal MRI scans) are at a high risk of developing CDMS (18) . Hence, when an individual presents with CIS, the challenge for the clinician is to determine the likelihood of the patient having CDMS. The ability to make an accurate diagnosis as early as possible is important for patient management, counseling, and optimal therapy (6, 26) . Diagnosis in patients with CIS is a clinical decision and should be made by a neurologist experienced in the relevant diagnosis (4).
Diagnostic criteria for MS have evolved over the past 50 years (6) . These criteria provide neurologists with a systematic approach for MS diagnosis (heavily based on MRI findings) for a range of clinical presentations, including CIS, RRMS, and primary progressive MS (18) . Although successive versions have differed in emphasis, all require the dissemination of the disease in space and time documented by either clinical, paraclinical, or laboratory criteria (6) . Recently, the International Panel on Diagnosis of Multiple Sclerosis has proposed new MRI criteria for the diagnosis of MS in patients with CIS. These criteria were developed in Western Caucasian populations and then studied in a Spanish cohort, and similar results were obtained with regard to sensitivity and specificity, hence reinforcing their usefulness in MS diagnosis. Currently, the international validation of the 2010 criteria is moving forward, and new information about their sensitivity and specificity has been provided for several MS populations (27) . S10
Patients with CIS with MRI-detected brain damage similar to that seen in MS are in the high-risk category for a second neurologic event. This group may benefit from early treatment with immunomodulators to delay the diagnosis of CDMS (28) . IFNb treatment is particularly effective in the early stages of MS, when the levels of inflammatory activity are highest, and has been shown to be effective and well tolerated in the treatment of patients with CIS in clinical trials (18) . Much has been learned in the past 10 years about CIS and its relation to MS. Robust and practical new diagnostic criteria aid earlier MS diagnosis in patients with typical CIS, and immunomodulatory treatments favorably modify the early clinical course (over 2-5 years) in those at a high risk of MS (1) .
